David B. Harrell just released a new comparative analysis on Marrow Cellution™ and the Harvest BMAC® System.
Amongst others, Dr. Harrell’s findings are:
- CFU-f counts were twice as many with Marrow Cellution™ compared to the final (concentrated) BMAC product.
- Marrow Cellution™ required significantly less aspirate than Harvest’s Bone Marrow Concentrate System.
- The preparation time was significantly lower with Marrow Cellution™ System.
The Marrow Cellution™ System is designed to minimize and eliminate the restrictive limitations associated with “point of care” processing systems which employ inefficient traditional aspiration trocar technology and are regulated as drugs “Advanced Therapies Medicinal Products (ATMP)”. Marrow Cellution™ is a minimally invasive bone/cell enriched autograft access and retrieval system, which does not require additional manipulation or processing, it never leaves the sterile field and provides rich autograft without associated morbidity.
Visit our Marrow Cellution product page